US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% META $728.08 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00% SPCX $158.96 ▲+0.00% JNJ $256.03 ▲+0.00%
FinancialContent

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

14.21 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
24 25 Next >
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Shares Fell Today: What's Going On? ↗
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares closed lower on Monday potentially following the company's announcement of Dan Kirby as Chief Commercial Officer. 
Via Benzinga
News headline image
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
What's Wrong With Iovance Biotherapeutics Stock? ↗
Via The Motley Fool
News headline image
Where Will Iovance Biotherapeutics Be in 5 Years? ↗
Via The Motley Fool
News headline image
Prediction: This Stock Will Beat the Market in 2025 ↗
Via The Motley Fool
News headline image
Peering Into Iovance Biotherapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts ↗
Via The Motley Fool
News headline image
3 Stocks That Could Turn $1,000 Into $5,000 by 2030 ↗
A handful of bullish factors are converging at the right time in the right way for all three of these companies. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Shares Are Falling Today: What's Going On? ↗
Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) are trading lower Friday. The company announced the inducement stock option grants under Nasdaq Listing Rule 5635(c)(4). 
Via Benzinga
News headline image
3 Mid-Cap Stocks That Could Take Off in 2025 ↗
Via The Motley Fool
News headline image
Is Iovance Biotherapeutics Stock a Millionaire Maker? ↗
Via The Motley Fool
News headline image
Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back ↗
Via The Motley Fool
News headline image
A Peek at Iovance Biotherapeutics's Future Earnings ↗
 
Via Benzinga
News headline image
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today ↗
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
If I Could Only Buy 3 Stocks in the Last Month of 2024, I'd Pick These ↗
These windows of opportunity aren't likely to remain open for much longer. 
Via The Motley Fool
News headline image
Is Iovance Biotherapeutics Stock a Buy? ↗
The biotech is making important breakthroughs, but is that enough? 
Via The Motley Fool
News headline image
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio? ↗
Via The Motley Fool
News headline image
3 Monster Stocks to Hold for the Next 10 Years ↗
Just be ready to ride out some inevitable turbulence along the way. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
2 Innovative Stocks That Could Deliver Outsize Returns ↗
Via The Motley Fool
News headline image
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More ↗
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
Iovance also to Participate in Upcoming November Conferences 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why Iovance Biotherapeutics Stock Triumphed on Thursday ↗
With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout. 
Via The Motley Fool
News headline image
3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow ↗
This biotech's growth story is going to start moving faster, and soon. 
Via The Motley Fool
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
24 25 Next >